Product logins

Find logins to all Clarivate products below.


Blog: Clinical trials

Here you will find relevant articles and insight into all Clarivate related products and news.

Europe looks to shore up global competitiveness with the E.U. Biotech Act Europe looks to shore up global competitiveness with the E.U. Biotech Act
Blog June 22, 2026
Europe looks to shore up global competitiveness with the E.U. Biotech Act
Biopharma Biotech Business Development
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials
De-risking next-generation bispecific antibodies: a target-centric approach to safety intelligence De-risking next-generation bispecific antibodies: a target-centric approach to safety intelligence
Blog June 9, 2026
De-risking next-generation bispecific antibodies: a target-centric approach to safety intelligence
Bispecific antibodies BsAb Clinical trials
The competitive signals hiding in plain sight for biopharma The competitive signals hiding in plain sight for biopharma
Blog May 8, 2026
The competitive signals hiding in plain sight for biopharma
Biopharma Business Development Clinical trials
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
Biopharma Biotech Clinical trials
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Tolebrutinib: when safety concerns override efficacy signals Tolebrutinib: when safety concerns override efficacy signals
Blog February 24, 2026
Tolebrutinib: when safety concerns override efficacy signals
Biopharma Biotech Clinical trials
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Blog February 24, 2026
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Biopharma Biotech Clinical trials

Clinical trials

Bringing the patient voice into clinical trials with clinical outcome assessments Bringing the patient voice into clinical trials with clinical outcome assessments
Blog November 10, 2022
Bringing the patient voice into clinical trials with clinical outcome assessments
Seven RNA technology companies to keep an eye on Seven RNA technology companies to keep an eye on
Blog November 8, 2022
Seven RNA technology companies to keep an eye on
Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022 Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022
Blog June 23, 2022
Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022
How a “fail fast” approach can set clinical trials up for success How a “fail fast” approach can set clinical trials up for success
Blog May 26, 2022
How a “fail fast” approach can set clinical trials up for success
clinical trials data clinical trials data
Blog March 17, 2022
Clinical trials and pregnancy: regulators weigh in
Bioinfogate becomes Clarivate Bioinfogate becomes Clarivate
Blog October 25, 2021
Bioinfogate becomes Clarivate
COVID-19: Fighting a global pandemic with innovation COVID-19: Fighting a global pandemic with innovation
Blog October 14, 2021
COVID-19: Fighting a global pandemic with innovation
Top oncology breakthroughs shared at ESMO 2021 Top oncology breakthroughs shared at ESMO 2021
Blog October 7, 2021
Top oncology breakthroughs shared at ESMO 2021
Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo
Blog June 23, 2021
Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo
KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma
Blog June 21, 2021
KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma